12:00 AM
 | 
Aug 28, 2000
 |  BC Week In Review  |  Company News  |  Deals

Antigenics, Aquila deal

AGEN will acquire AQLA for 2.5 million AGEN shares, for a total value of $40 million. AQLA shareholders will receive 0.2898 AGEN shares for each share of AQLA, valuing...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >